grant

The role of early oncogenic drivers in maintaining lineage fidelity in prostate cancer

Organization WEILL MEDICAL COLL OF CORNELL UNIVLocation NEW YORK, UNITED STATESPosted 1 Jun 2025Deadline 30 Apr 2030
NIHUS FederalResearch GrantFY2026AffectAfter CareAfter-TreatmentAftercareAndrogen ReceptorAndrogenic AgentsAndrogenic CompoundsAndrogensAntioncogene Protein p53BackBiologic ModelsBiologicalBiological MarkersBiological ModelsBiologyCancersCellular Tumor Antigen P53CharacteristicsChromatinClinicalClinical TrialsDNA AlterationDNA Sequence AlterationDNA mutationDataDependenceDiseaseDisorderDorsumEndocrine TherapyEquilibriumEvolutionFoundationsGEM modelGEMM modelGene TranscriptionGenetic AlterationGenetic ChangeGenetic TranscriptionGenetic defectGenetic mutationGenetically Engineered MouseHistologicHistologicallyHormonal TherapyHumanIn VitroInstitutionInvestigatorsMaintenanceMalignant NeoplasmsMalignant TumorMalignant neoplasm of prostateMalignant prostatic tumorMediatingMediatorModel SystemModelingModern ManMolecularMutationNatural HistoryNeuroendocrineNeuroendocrine SystemNeurosecretory SystemsOncogenicOncoprotein p53OrganoidsP53Pathway interactionsPatientsPatternPhenotypePhosphoprotein P53Phosphoprotein pp53Precision therapeuticsPreventative strategyPrevention strategyPreventive strategyProstateProstate CAProstate CancerProstate GlandProstate malignancyProstatic GlandProtein TP53RB1RB1 geneRNA ExpressionReceptor SignalingRecurrenceRecurrentResearch PersonnelResearchersResistanceRoleSamplingSequence AlterationShapesSignal PathwaySpecificityTP53TP53 geneTRP53TherapeuticTherapeutic AndrogenTherapeutic HormoneTimeTranscriptionTranscription ProcessTranscriptional ControlTranscriptional RegulationTumor Protein p53Tumor Protein p53 GeneTumor Subtypeandrogen dependentandrogen independent prostate cancerandrogen indifferent prostate cancerandrogen insensitive prostate cancerandrogen resistance in prostate cancerandrogen resistant prostate cancerandrogen responsiveandrogen sensitivebalancebalance functionbio-markersbiologicbiologic markerbiomarkercastration resistant CaPcastration resistant PCacastration resistant prostate cancerclinical relevanceclinically relevantendocrine treatmentepigenomicsgenetically engineered mouse modelgenetically engineered murine modelgenome mutationgenomic alterationhormonal treatmenthormone refractory prostate cancerhormone therapyhormone treatmenthuman datain vivo Modelinnovateinnovationinnovativeinsightmalignancymouse modelmultidisciplinarymurine modelmutantneoplasm/cancernovelp53 Antigenp53 Genesp53 Tumor Suppressorpathwaypersonalized health interventionpersonalized interventionpost treatmentprecision interventionsprecision therapiesprecision treatmentpreventpreventingprogramsprostate cancer modelprostate cancer resistant to androgenprostate tumor modelprotein p53receptor functionresistance mechanismresistance to therapyresistantresistant mechanismresistant to therapyresponseretinoblastoma-1single cell analysissocial roletargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic resistancetherapy resistanttimelinetranscriptomicstreatment resistancetreatment strategytumor
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Description preview

PROJECT SUMMARY/ABSTRACT
Prostate cancer (PCa) is a clinically and molecular heterogenous disease, with biologically distinct subtypes

driven by characteristic genomic alterations in both early, untreated disease and treatment resistant castration-

resistant prostate cancer (CRPC). However, whether early alterations affect fidelity to prostate…

🔒

Full details available on the Agency plan

Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.

Start 7-day free trial — $29.99/mo →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →
The role of early oncogenic drivers in maintaining lineage fidelity in prostate cancer — WEILL MEDICAL COLL OF CORNELL U | Dev Procure